09 November 2020 - BEAM AllianceAntibiorésistance : Anticiper une nouvelle crise sanitaireFlorence Séjourné, présidente de BEAM Alliance : « Il faut anticiper les investissements en R&D dès maintenant pour avoir un…read more >>
28 August 2020 - BEAM AllianceBEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibioticsBEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibioticsread more >>
27 August 2020 - BEAM AllianceBEAM Alliance – Reflection paper on the AMR Action FundThe COVID-19 pandemic has stressed how drug and vaccine development requires time and resources. Whilst we welcome the launch of…read more >>
10 July 2020 - BEAM AllianceBEAM Alliance – Reflection paper on the EU Pharmaceutical Strategy RoadmapBEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…read more >>
02 April 2020 - BEAM AllianceRequest for Proposals (RFP) for an Agreement for Performance of Work (APW) to develop an online e-learning course on antimicrobial stewardshipTo support the Antimicrobial Stewardship and Awareness (ASA) Unit in the Global Coordination and Partnership on Antimicrobial Resistance (GCP) department…read more >>
03 December 2019 - BEAM AllianceNew IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistanceThe aim of the IMI Antimicrobial Resistance (AMR) Accelerator is to progress the development of new medicines to treat or…read more >>
22 July 2024 - Destiny Pharma plcDestiny Pharma: Treatment of XF-73 Nasal reduces antibiotic useThe data to be presented at ID Week highlights the ability of XF-73 Nasal gel to significantly reduce the need…read more >>
10 July 2024 - tamrisaTamrisa announces its emergence as a new specialized pharma venture dedicated to tackling anti microbial resistance (AMR) through Innovation, Stewardship and Access.Tamrisa is a specialized pharma venture dedicated to tackling Anti-Microbial Resistance (AMR) through Innovation, Stewardship and Access.read more >>
02 July 2024 - DevsHealth SLIGTP and DevsHealth join forces to develop new antibiotics against hospital-acquired infections by multi-resistant Staphylococcus aureusThe partnership will leverage DevsHealth’s DeepTech platform and IGTP’s extensive bacterial collection to discover new drugs against a major threat…read more >>
18 June 2024 - Destiny Pharma plcDestiny Pharma: Efficacy of XF-70 in Fungal Skin InfectionsThis XF-70 data presents an exciting opportunity for Destiny Pharma to address a growing patient need, while demonstrating the expanded…read more >>
11 June 2024 - Hypharm GmbHHYpharm: Innovative Phage Lysin HY-133 enters phase I clinical studyHY-133 is specifically effective against the bacterial pathogen Staphylococcus aureus including multi-resistant strains (MRSA, methicillin-resistant S. aureus) and is intended…read more >>
11 June 2024 - Destiny Pharma plcDestiny Pharma’s XF-73 Nasal Awarded MHRA ILAPMHRA's backing of XF-73 for the innovative medicines pathway is a key step that should enhance the clinical development of…read more >>
25 March 20259th AMR ConferenceSave the date! The 9th AMR Conference will be organized as a face-to-face event on 25-26 February 2025, in Basel.…read more >>
04 November 2024BIO-Europe ® 2024 – 30th Annual International Partnering ConferenceOver the last 30 years, BIO-Europe, has become Europe’s flagship partnering event. Its international reach makes it a one-of-a-kind offering,…read more >>
22 August 2024REVIVE Webinar: Exploring non-traditional antimicrobials: Insights from three casesFind out the latest in the development of non-traditional antimicrobials from Jennifer Schneider at Centauri Therapeutics, Rida Mourtada at Lytica…read more >>
23 July 2024REVIVE Webinar: The value of surveillance data in defining the medical need for new antimicrobialsIn this webinar, the speakers will show the value of susceptibility surveillance data in defining the need for new antibacterials,…read more >>
27 June 2024REVIVE Webinar: Progressing an antibacterial drug discovery project – an SME perspectiveAlisa Serio from Paratek Pharma and Victoria Savage from INFEX Therapeutics will focus on the particular challenges, progression criteria and…read more >>
23 April 2024REVIVE Webinar: Efflux inhibitors: A strategy to tackle multidrug resistanceThe next REVIVE webinar will feature an overview of bacterial efflux and how molecules designed to inhibit this can be…read more >>
18 April 2024BEAM webinar – Swiss RTA: Why do we need a pull incentive to push antibiotics onto the market?BEAM is excited to host a series of webinars setup by its Associated Organizations.read more >>
09 April 2024REVIVE Webinar: Progressing a discovery project – Criteria and challengeswith Ken Bradley, Global Head, Infectious Disease Discovery, Roche and Diarmaid Hughes, Professor of Medical Molecular Bacteriology, Uppsala University (Sweden)read more >>
21 March 2024BEAM webinar – BioAster: Novel technologies with an AI-facilitated approachBEAM is excited to host a series of webinars setup by its Associated Organizations.read more >>